Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Science. 2019 Jun 28;364(6447):1283-1287. doi: 10.1126/science.aaw8981. Epub 2019 Jun 27.
Drugs targeting the orthosteric, primary binding site of G protein-coupled receptors are the most common therapeutics. Allosteric binding sites, elsewhere on the receptors, are less well-defined, and so less exploited clinically. We report the crystal structure of the prototypic β-adrenergic receptor in complex with an orthosteric agonist and compound-6FA, a positive allosteric modulator of this receptor. It binds on the receptor's inner surface in a pocket created by intracellular loop 2 and transmembrane segments 3 and 4, stabilizing the loop in an α-helical conformation required to engage the G protein. Structural comparison explains the selectivity of the compound for β- over the β-adrenergic receptor. Diversity in location, mechanism, and selectivity of allosteric ligands provides potential to expand the range of receptor drugs.
靶向 G 蛋白偶联受体的正位、主要结合位点的药物是最常见的治疗药物。位于受体上其他位置的变构结合位点定义不明确,因此在临床上的应用也较少。我们报告了原型β-肾上腺素能受体与正位激动剂和化合物 6FA 复合物的晶体结构,该化合物是该受体的正变构调节剂。它结合在受体的内表面上,位于由细胞内环 2 和跨膜片段 3 和 4 形成的口袋中,稳定了环,使其处于与 G 蛋白结合所需的α螺旋构象。结构比较解释了该化合物对β-肾上腺素能受体的选择性。变构配体的位置、机制和选择性的多样性为扩大受体药物的范围提供了潜力。